Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I share my experiences (good and bad) in trading stocks and results of thousands of trading simulations in my books. My primary book is Complete The Art of Investing (http://www.amazon.com/dp/B01AASN2GA).
My blog is http://tonyp4idea.blogspot.com.
Retired early from IT and work full-time in investing. Develop strategies to trade. It is my passion to check out why some strategies work and why some only work in certain market conditions.
Dr. Milo Jones is a Managing Director at Inveniam Strategy and at Insight Advisory Partners (a Chicago-based merchant bank and strategy consulting firm specializing in the food and beverage sector).
Milo has spent 20 years as a consulting and finance professional in both the US and Europe, including time with both Morgan Stanley Dean Witter in New York and Accenture in London. Before going into business, he served four years as an officer in the US Marine Corps.
Milo speaks and writes widely on macroeconomic and geopolitical issues for venues like Institutional Investor Forums, and occasionally teaches strategy and advanced finance courses as a Visiting Professor in the Masters programs of IE Business School in Madrid, Spain.
Milo holds a BA from Northwestern University, an MBA from London Business School, and an MA (Hons) and PhD in International Relations from the University of Kent.
He is the co-author of Constructing Cassandra: Reframing Intelligence Failure at the CIA, 1947-2001, published by Stanford University Press in 2013, which explores strategic surprises at the Agency.
Michael Pettis is a professor at Peking University's Guanghua School of Management, where he specializes in Chinese financial markets. He has also taught, from 2002 to 2004, at Tsinghua University’s School of Economics and Management and, from 1992 to 2001, at Columbia University’s Graduate School of Business.
Pettis has worked on Wall Street in trading, capital markets, and corporate finance since 1987, when he joined the Sovereign Debt trading team at Manufacturers Hanover (now JP Morgan). Most recently, from 1996 to 2001, Pettis worked at Bear Stearns, where he was Managing Director-Principal heading the Latin American Capital Markets and the Liability Management groups.
Visit: China Financial Markets (http://www.mpettis.com)
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Motto: I invest in undervalued (i.e. cheap) well-established companies trading at a below market multiple.
The companies that I invest in are large stable companies with proven track records. My goal is the highest total return possible with the least amount of risk.
Professional Background: I am a healthcare practitioner with extensive experience in the pharmaceutical sector. I have a passion for investing honed over the past twenty years through various market cycles.